Villavicencio

Researchers are evaluating tozorakimab as an additional treatment to standard care in adults hospitalized with viral lung infection who need supplemental oxygen. The study aims to determine if tozorakimab can help prevent death or the need for invasive mechanical ventilation or extracorporeal membrane oxygenation. This Phase III trial involves a large group of participants to assess the safety and effectiveness of this approach. Participants are randomly assigned to one of two groups one group receives a single intravenous dose of tozorakimab on the first day, while the other group receives a matching placebo. The study uses a double-blind design, meaning neither participants nor researchers know which treatment is given. This helps ensure unbiased results. The treatments are given once, and participants continue to receive standard care during the trial. During the study, participants are closely monitored and evaluated up to 60 days after treatment. Researchers track important outcomes such as death rates, progression to invasive ventilation, days alive outside intensive care, and oxygen use. They also assess clinical progression using a World Health Organization scale and monitor for any anti-drug antibodies. The trial lasts until November 2027, with multiple assessments throughout to understand the treatments impact and safety.

Researchers are investigating factors associated with mortality in the intensive care unit ICU and evaluating the performance of the APACHE II score as a tool to predict mortality. The study focuses on critically ill adult patients admitted to the ICU in a hospital in Villavicencio, Colombia. It addresses the need to validate this score within a different population and healthcare setting, as current data in Colombia are limited. This observational study reviews records of all adult patients admitted to the ICU from January 2022 to June 2025, excluding those in intermediate care with lower therapeutic intervention scores. Data collected include demographic details, diagnosis, APACHE II and TISS-28 severity scores, mechanical ventilation duration, and outcomes such as mortality and ICU length of stay. Patients are grouped based on whether they died within 28 days or survived and were discharged alive within 24 days. Participants medical information is gathered retrospectively from clinical charts and entered into a standardized database. The APACHE II score is calculated within the first 24 hours of ICU admission. Researchers analyze mortality rates by disease and admission type, factors linked to mortality, and compare observed versus predicted mortality using statistical methods. The main outcome measured is mortality within 28 days, with careful monitoring of ICU stay and ventilation duration. The study is approved by an ethics committee and classified as low-risk research.

Researchers are investigating the factors linked to severe trauma outcomes, including mortality, among patients admitted to intensive care units ICUs in general hospitals across the Colombian Orinoco region. This study focuses on trauma, the leading cause of death and disability in young populations worldwide, often caused by violence and vehicle accidents. By analyzing trauma admissions and comparing them to other ICU admissions, the study aims to identify key predictors of trauma mortality and outcomes. The study involves reviewing ICU discharge records over a two-year period from January 2022 to December 2024 at two hospitals in Villavicencio, Colombia. Patients are grouped into those admitted for trauma-related reasons and those admitted for other diagnoses. The researchers will analyze demographic data, severity scores, and diagnoses to understand differences and factors associated with trauma outcomes. Participants medical records will be examined to assess mortality within 30 days and length of ICU stay. The study will highlight causes of trauma admissions, severity, and outcomes for different trauma types. The goal is to develop a predictive model tailored to the local population to help improve resource allocation, treatment strategies, and potentially reduce mortality and complications. The study extends through 2028 and is observational, reviewing existing hospital data without direct patient intervention.

Researchers are conducting a descriptive cross-sectional study to evaluate stroke events in a hospital located in the Orinoco region of Colombia. The study aims to analyze patient data from a stroke registry to understand care patterns, treatment delays, and adherence to clinical guidelines. This registry is reviewed monthly by a scientific committee to improve healthcare quality and standardize treatments for stroke patients. The study involves collecting demographic information, disease data, and discharge outcomes from patients admitted to the emergency room with suspected stroke based on neurological deficits or headache. Data is systematically gathered in a database called RES-Q, and the records will be reviewed and analyzed using statistical methods during the study period. The study does not include any interventions or treatments as it is observational. Participants will be adults diagnosed with stroke, whose clinical and CT findings confirm the condition. Researchers will assess the participants functional condition 30 days after the stroke event. The study relies on reviewing existing patient records and does not require active treatment or visits beyond routine care. The total study duration extends until April 2027, allowing comprehensive data collection and analysis.